Patron Partners LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 20.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,267 shares of the biopharmaceutical company’s stock after selling 1,339 shares during the quarter. Patron Partners LLC’s holdings in Pfizer were worth $270,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently modified their holdings of the business. Harbor Investment Advisory LLC increased its stake in shares of Pfizer by 3.6% during the 4th quarter. Harbor Investment Advisory LLC now owns 23,977 shares of the biopharmaceutical company’s stock worth $1,229,000 after purchasing an additional 825 shares during the last quarter. Saxon Interests Inc. raised its stake in shares of Pfizer by 12.9% in the third quarter. Saxon Interests Inc. now owns 8,309 shares of the biopharmaceutical company’s stock valued at $367,000 after buying an additional 951 shares during the period. Platte River Wealth Advisors LLC lifted its position in shares of Pfizer by 62.8% during the 3rd quarter. Platte River Wealth Advisors LLC now owns 12,717 shares of the biopharmaceutical company’s stock valued at $556,000 after buying an additional 4,905 shares during the last quarter. Accuvest Global Advisors raised its stake in Pfizer by 16.6% in the 3rd quarter. Accuvest Global Advisors now owns 12,994 shares of the biopharmaceutical company’s stock valued at $569,000 after acquiring an additional 1,848 shares during the period. Finally, Secure Asset Management LLC lifted its holdings in Pfizer by 3.5% during the fourth quarter. Secure Asset Management LLC now owns 15,835 shares of the biopharmaceutical company’s stock valued at $811,000 after purchasing an additional 537 shares during the last quarter. 67.62% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on PFE. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price target on shares of Pfizer in a research report on Wednesday, February 1st. BMO Capital Markets lowered their target price on shares of Pfizer from $55.00 to $53.00 and set an “outperform” rating on the stock in a report on Wednesday, February 1st. JPMorgan Chase & Co. set a $45.00 price target on Pfizer in a report on Monday, February 27th. The Goldman Sachs Group upgraded Pfizer from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $47.00 to $60.00 in a research note on Tuesday, December 13th. Finally, Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 target price for the company. in a report on Wednesday, January 4th. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $49.93.
Insiders Place Their Bets
Pfizer Price Performance
PFE opened at $41.50 on Monday. The company has a current ratio of 1.22, a quick ratio of 1.00 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $234.24 billion, a P/E ratio of 7.57, a PEG ratio of 1.40 and a beta of 0.64. The stock has a 50-day moving average price of $41.66 and a 200-day moving average price of $45.47. Pfizer Inc. has a 12-month low of $39.23 and a 12-month high of $56.32.
Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The business had revenue of $24.30 billion for the quarter, compared to analysts’ expectations of $24.40 billion. During the same period in the previous year, the firm earned $1.08 EPS. The business’s quarterly revenue was up 1.9% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 3.3 earnings per share for the current fiscal year.
About Pfizer
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Further Reading
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Novartis Shares Leap On Positive Clinical Trial Data
- MarketBeat Week in Review – 4/3 – 4/7
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
